ORAGENICS INC
OGENNYSEHealthcare · Pharmaceutical Preparations · FL · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $37,653 | $131,521 | $86,987 | — |
| Operating income | −$9.4M | −$10.6M | −$20.9M | −$14.4M | −$15.8M | −$26.6M |
| Net income | −$9.8M | −$10.6M | −$20.7M | −$14.3M | −$15.7M | −$26.4M |
| Total assets | $10.1M | $1.5M | $5.0M | $14.8M | $28.2M | $18.7M |
| Total liabilities | $1.8M | $1.7M | $1.8M | — | — | — |
| Equity | $8.3M | −$211,885 | $3.2M | $13.0M | $26.5M | $16.8M |
| EPS (diluted) | $-4.56 | $-47.88 | $-9.18 | $-7.11 | $-8.09 | — |
| Shares out. | 21.5M | 4.5M | 2.0M | 116.4M | 109.6M | 46.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −118.9%
- Return on assets
- −97.8%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 17.7%
- Debt / equity
- 0.22×
- Book value / share
- $0.39
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −5.9%clean
- Piotroski F-Score
- 3/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2023
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2012
- NT 10-Qmissed a reporting deadline ↗May 15, 2009
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2009
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Sabby Management, LlcPassive (13G)Jan 21, 2026
- Five Narrow Lane LpPassive (13G)Jul 2, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 656,580 | 11.8 | -4.0% |
| Apr 30, 2026 | 683,948 | 11.1 | -2.8% |
| Apr 15, 2026 | 703,470 | 12.2 | -2.3% |
| Mar 31, 2026 | 720,353 | 5.5 | -9.1% |
| Mar 13, 2026 | 792,779 | 1.8 | +39.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosure · Other material eventMay 19, 2026
- Other material eventMay 7, 2026
- Other material eventApr 13, 2026
- Item 5.08Mar 31, 2026
- Other material eventMar 11, 2026
- Entered a material agreementJan 22, 2026
- Regulation FD disclosureJan 20, 2026
- Director / officer changeDec 15, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.